Managing Your Care with ACTN2-Related Disease
At a Glance
ACTN2-related disease has no single treatment plan. Care is tailored to each person and may include coordinated neuromuscular, heart, lung, rehabilitation, and genetics specialists, with monitoring and support for muscle weakness, breathing, heart rhythm, and daily function.
Because ACTN2-related disease is so rare and its symptoms are so variable, there is no single “standard” treatment protocol or cure. Instead, care is highly individualized and focuses on managing the specific symptoms you or your child experience [1][2]. This is best achieved through a multidisciplinary care team—a group of specialists who coordinate your treatment [3].
Your team may include:
- Neuromuscular Specialist: A neurologist who manages muscle weakness and monitors disease progression [1].
- Cardiologist: To monitor heart structure and rhythm [4].
- Pulmonologist: To check the strength of the muscles you use for breathing [5].
- Physical and Occupational Therapists: To help maintain mobility and independence in daily life [3].
- Genetic Counselor: To help your family understand inheritance risks and navigate testing for relatives [6].
Skeletal Muscle, Physical Therapy, and Practical Living
Maintaining mobility is a primary goal. However, because ACTN2-related disease affects the structural integrity of your muscle fibers, exercise must be individualized.
- Guided Exercise: Physical therapy (PT) is essential for maintaining range of motion and muscle health [3]. Your therapist should tailor a paced, submaximal aerobic and strengthening plan. You do not need to fear movement, but you should avoid exhaustion and any activities restricted by your specific cardiac or respiratory status [3].
- Daily Accommodations: Practical care involves managing fatigue and energy conservation, assessing the need for mobility devices to prevent falls, and organizing school or work accommodations.
- Bone Health: In cases of early-onset muscle weakness, doctors may monitor bone mineral density and recommend vitamin D and calcium based on your dietary intake and laboratory results [7].
Respiratory Health and Monitoring
The muscles that help you breathe can be affected, and this neuromuscular hypoventilation can be “silent,” appearing across multiple phenotypes rather than just congenital cases [2].
- Regular Testing: Your pulmonologist may use spirometry, serial sitting and supine pulmonary-function measures, respiratory-muscle strength testing, and cough assessments to see how well your breathing muscles are working [5][8].
- Sleep Studies: If you experience morning headaches, daytime sleepiness, shortness of breath when lying flat, or if your lung function declines, your doctor may order a sleep study (polysomnography) or nocturnal oximetry to check for hypoventilation (shallow breathing) while you sleep [9][10].
- Breathing Support: If hypoventilation is found, a specialist may prescribe bilevel Non-Invasive Ventilation (NIV)—such as a BiPAP machine used at night—to help support your breathing muscles and improve your quality of life [11][10].
Proactive Heart Care
Cardiac management follows standard guidelines for the specific type of heart involvement found during your screening [12][13].
- Managing Rhythm: If tests show a risk for dangerous irregular heartbeats (arrhythmias), some patients may need an Implantable Cardioverter-Defibrillator (ICD), a device that can monitor and reset the heart’s rhythm if it becomes life-threatening [12][14].
- Medication: In rare reported cases where a variant caused a prolonged QTc interval (an electrical delay), rhythm management was utilized. However, the treatment of prolonged QT depends on the exact electrical abnormality and specialized electrophysiology assessment. You should never start or stop a cardiac medication without explicit guidance from your cardiologist [4].
The Role of Genetic Counseling
Because the relationship between a specific ACTN2 variant and the resulting symptoms (genotype-phenotype correlation) is not yet fully understood, genetic counseling is vital [6]. A counselor can help you decide which family members should be tested and explain what the results might mean for their future health and family planning [1][15]. Since variants can be passed down or appear for the first time (de novo), a counselor ensures that your family receives the most accurate information available [2].
Common questions in this guide
Which specialists should be involved in ACTN2-related disease care?
How is ACTN2-related disease managed?
What exercise is safe for someone with ACTN2-related disease?
How are breathing problems monitored in ACTN2-related disease?
What heart monitoring or treatment might be needed?
Should relatives have genetic testing for an ACTN2 variant?
Get notified when new evidence is published on ACTN2-related cardiac and skeletal myopathy.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (15)
- 1
Clinical and imaging spectrum of non-congenital dominant ACTN2 myopathy.
Iruzubieta P, Verdú-Díaz J, Töpf A, et al.
Journal of neurology 2025; (272(2)):150 doi:10.1007/s00415-025-12893-9.
PMID: 39812845 - 2
ACTN2 mutations cause "Multiple structured Core Disease" (MsCD).
Lornage X, Romero NB, Grosgogeat CA, et al.
Acta neuropathologica 2019; (137(3)):501-519 doi:10.1007/s00401-019-01963-8.
PMID: 30701273 - 3
Exercise Training as Part of Musculoskeletal Management for Congenital Myopathy: Where Are We Now?
Adaikina A, Hofman PL, O'Grady GL, Gusso S
Pediatric neurology 2020; (104()):13-18 doi:10.1016/j.pediatrneurol.2019.10.008.
PMID: 31926608 - 4
Disease modeling of a mutation in α-actinin 2 guides clinical therapy in hypertrophic cardiomyopathy.
Prondzynski M, Lemoine MD, Zech AT, et al.
EMBO molecular medicine 2019; (11(12)):e11115 doi:10.15252/emmm.201911115.
PMID: 31680489 - 5
Respiratory function in LAMA2-related muscular dystrophy and SELENON-related congenital myopathy, a 1.5-year natural history study.
Bouman K, van Doorn JLM, Groothuis JT, et al.
European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society 2024; (48()):30-39 doi:10.1016/j.ejpn.2023.11.005.
PMID: 38008001 - 6
Mutation update for the ACTN2 gene.
Ranta-Aho J, Olive M, Vandroux M, et al.
Human mutation 2022; (43(12)):1745-1756 doi:10.1002/humu.24470.
PMID: 36116040 - 7
Bone Quality in Patients with a Congenital Myopathy: A Scoping Review.
Bouman K, Dittrich ATM, Groothuis JT, et al.
Journal of neuromuscular diseases 2023; (10(1)):1-13 doi:10.3233/JND-221543.
PMID: 36314217 - 8
Myopathology in congenital myopathies.
Sewry CA, Wallgren-Pettersson C
Neuropathology and applied neurobiology 2017; (43(1)):5-23 doi:10.1111/nan.12369.
PMID: 27976420 - 9
Characteristics and feasibility of ambulatory respiratory assessment of paediatric neuromuscular disease: an observational retrospective study.
Zhang C, Wei CJ, Jin Z, et al.
The International journal of neuroscience 2023; (133(9)):1045-1054 doi:10.1080/00207454.2022.2042691.
PMID: 35289716 - 10
Long term noninvasive ventilation and continuous positive airway pressure in children with neuromuscular diseases in France.
Allaer L, Khirani S, Griffon L, et al.
Neuromuscular disorders : NMD 2022; (32(11-12)):886-892 doi:10.1016/j.nmd.2022.09.008.
PMID: 36270935 - 11
A Diagnostic Challenge in an Adolescent with Collagen VI-Related Myopathy and Emotional Disorder-Case Report.
Oros M, Baranga L, Glangher A, et al.
Journal of personalized medicine 2023; (13(11)) doi:10.3390/jpm13111577.
PMID: 38003892 - 12
The Paradigm of Sudden Death Prevention in Hypertrophic Cardiomyopathy.
Maron MS, Rowin EJ, Maron BJ
The American journal of cardiology 2024; (212S()):S64-S76 doi:10.1016/j.amjcard.2023.10.076.
PMID: 38368038 - 13
Management of Hypertrophic Cardiomyopathy: JACC State-of-the-Art Review.
Maron BJ, Desai MY, Nishimura RA, et al.
Journal of the American College of Cardiology 2022; (79(4)):390-414 doi:10.1016/j.jacc.2021.11.021.
PMID: 35086661 - 14
Non-invasive markers for sudden cardiac death risk stratification in dilated cardiomyopathy.
Pooranachandran V, Nicolson W, Vali Z, et al.
Heart (British Cardiac Society) 2022; (108(13)):998-1004 doi:10.1136/heartjnl-2021-319971.
PMID: 34670824 - 15
Recurring homozygous ACTN2 variant (p.Arg506Gly) causes a recessive myopathy.
Donkervoort S, Mohassel P, O'Leary M, et al.
Annals of clinical and translational neurology 2024; (11(3)):629-640 doi:10.1002/acn3.51983.
PMID: 38311799
This page is for informational purposes only and does not constitute medical advice about ACTN2-related disease. Your neuromuscular, heart, breathing, and genetics specialists should tailor monitoring and treatment to your needs.